Dual inhibition of c‐abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis-Reference-Cited by-同舟云学术

Dual inhibition of c‐abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis

Published:2008-03-07 Issue:7 Volume:22 Page:2214-2222
ISSN:0892-6638
Container-title:The FASEB Journal
language:en
Short-container-title:FASEB j.

Author:

Akhmetshina Alfiya¹,Dees Clara¹,Pileckyte Margarita²,Maurer Britta³,Axmann Roland¹,Jüngel Astrid³,Zwerina Jochen¹,Gay Steffen³,Schett Georg¹,Distler Oliver³,Distler Jörg H. W.¹

Affiliation:

1. Department of Internal Medicine 3 and Institute for Clinical ImmunologyUniversity of Erlangen-NurembergErlangenGermany

2. Department of RheumatologyKaunas Medical University HospitalKaunusLithuania

3. Center of Experimental Rheumatology and Zurich Center of Integrative Human PhysiologyUniversity Hospital of ZurichZurichSwitzerland

Funder

Elan

German-Russian Interdisciplinary Science Center

Publisher

Wiley

Subject

Genetics,Molecular Biology,Biochemistry,Biotechnology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1096/fj.07-105627

Reference29 articles.

1. CARBOXYTERMINAL TYPE I PROCOLLAGEN PEPTIDE CONCENTRATIONS IN SYSTEMIC SCLEROSIS: HIGHER LEVELS IN EARLY DIFFUSE DISEASE

2. Mortality and causes of death in a Swedish series of systemic sclerosis patients

3. Systemic sclerosis: a prototypic multisystem fibrotic disorder

4. Liver fibrosis induced by hepatic overexpression of PDGF-B in transgenic mice

5. Topical Application of a Peptide Inhibitor of Transforming Growth Factor-β1 Ameliorates Bleomycin-Induced Skin Fibrosis

Cited by 176 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The ‘whole landscape’ of research on systemic sclerosis over the past 73 years;Autoimmunity Reviews;2024-05

2. Comparison of long‐term outcomes between imatinib and dasatinib prophylaxis after allogeneic stem cell transplantation in patients with Philadelphia‐positive acute lymphoblastic leukemia: A multicenter retrospective study;Cancer;2024-02-05

3. Comparison of cutaneous adverse events between second-generation tyrosine kinase inhibitors and imatinib for chronic myeloid leukemia: a systematic review and meta-analysis;Acta Oncologica;2023-10-03

4. Therapeutic potential of vasculogenic mimicry in urological tumors;Frontiers in Oncology;2023-09-21

5. Drug development and novel therapeutics to ensure a personalized approach in the treatment of systemic sclerosis;Expert Review of Clinical Immunology;2023-06-29